

Advances in Understanding the Behavioral and Neurobiological Underpinnings of Motivational Deficits in Schizophrenia

George Foussias, MD PhD FRCPC

Clinician-Scientist, Campbell Family Research Institute and Schizophrenia Division, Centre for Addiction and Mental Health

Assistant Professor, Department of Psychiatry and Institute of Medical Science, University of Toronto, Toronto, Canada


Disclosure slide

Conflict of interests	See below
Relevant relationships with companies	Companies
<ul style="list-style-type: none">• Sponsoring or research money• Fee or other reimbursement (speaker's fees)• Shareholder• Other relationship – Advisory Board	<ul style="list-style-type: none">• Neurocrine Bioscience, Medicure• Hoffman La-Roche, Novartis, Lundbeck• n/a• Hoffman La-Roche

Objectives

- To review the phenomenology and functional consequences of motivational deficits in schizophrenia
- To examine behavioural impairments across discrete facets of motivation in schizophrenia
- To explore recent findings on the neurobiology of cost/effort valuation in schizophrenia

Historical Perspective



Historical Perspective

When the patient lashes out against "them"—

THORAZINE®
brand of chlorpromazine


quickly puts an end to his violent outburst

'Thorazine' is especially effective when the psychotic episode is triggered by delusions or hallucinations.

At the outset of treatment, Thorazine's combination of antipsychotic and sedative effects provides both emotional and physical calming. Assaultive or destructive behavior is rapidly controlled.

As therapy continues, the initial sedative effect gradually disappears. But the antipsychotic effect continues, helping to dispel or modify delusions, hallucinations and confusion, while keeping the patient calm and approachable.


SK & F SMITH KLINE & FRENCH LABORATORIES
leaders in psychopharmaceutical research



A reminder advertisement — For prescribing information, please see PDR or available literature.



Domains of Psychopathology




The Negative Symptoms

- Affective flattening
- Alogia
- Asociality
- Avolition
- Anhedonia




The Negative Symptoms




Mueser et al. 1994
Sayers et al. 1996
Kelley et al. 1999
Peralta & Cuesta 1999
Kimhy et al. 2006
Foussias & Remington 2010
Messinger et al. 2011
Liemburg et al. 2013
Strauss et al. 2013
Fervaha et al. 2014

Functional Outcomes in Schizophrenia

WHO-ISOS
Social adjustment over 13 years¹



Cumulative Recovery Rates in First-Episode Schizophrenia²



Functional Outcomes in Schizophrenia

Article

Predictive Values of Neurocognition and Negative Symptoms on Functional Outcome in Schizophrenia: A Longitudinal First-Episode Study With 7-Year Follow-Up

Peter Milev, M.D., Ph.D.

Beng-Choon Ho, M.R.C.Psych.

Stephan Arndt, Ph.D.

Nancy C. Andreasen, M.D., Ph.D.

Objective: The relationship between cognition and outcome in people with schizophrenia has been established in studies that, for the most part, examined chronic patients and were cross-sectional in design. The purpose of this study was to analyze the relationships between neurocognitive variables assessed at illness

Results: Verbal memory, processing speed and attention, and the severity of negative symptoms at intake were related to subsequent outcome. Global psychosocial functioning was predicted by negative symptoms and attention. Verbal memory was the significant predictor of the degree of impairment in recreational activities.

(*Am J Psychiatry* 2005; 162:495–506)

Schizophrenia Bulletin vol. 31 no. 1 pp. 167–174, 2005
doi:10.1093/schbul/sbi004
Advance Access publication on February 16, 2005

Symptoms Versus Neurocognitive Test Performance as Predictors of Psychosocial Status in Schizophrenia: A 1- and 4-Year Prospective Study

Matthew M. Kurtz, Paul J. Moberg, J. Daniel Ragland, Ruben C. Gur, and Raquel E. Gur



Contents lists available at ScienceDirect

Schizophrenia Research

journal homepage: www.elsevier.com/locate/schres



Determinants of everyday outcomes in schizophrenia: The influences of cognitive impairment, functional capacity, and symptoms

Feea R. Leifker^a, Christopher R. Bowie^b, Philip D. Harvey^{a,*}



Contents lists available at SciVerse ScienceDirect

Schizophrenia Research

journal homepage: www.elsevier.com/locate/schres



Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data

Jonathan Rabinowitz^{a,*}, Stephen Z. Levine^b, George Garibaldi^c, Dragana Bugarski-Kirola^c, Carmen Galani Berardo^c, Shitij Kapur^d

Functional Outcomes in Schizophrenia

Schizophrenia Research 116 (2010) 20–26



ELSEVIER

Contents lists available at [ScienceDirect](#)

Schizophrenia Research

journal homepage: www.elsevier.com/locate/schres



Apathy in first episode psychosis patients: One year follow up

Ann Faerden ^{a,*}, Arnstein Finset ^b, Svein Friis ^{a,c}, Ingrid Agartz ^{c,d}, Elizabeth Ann Barrett ^e, Ragnar Nesvåg ^d, Ole A. Andreassen ^{a,c}, Stephen R. Marder ^{f,g}, Ingrid Melle ^{a,c}

Psychiatry Research 210 (2013) 665–668



ELSEVIER

Contents lists available at [ScienceDirect](#)

Psychiatry Research

journal homepage: www.elsevier.com/locate/psychres



Amotivation and functional outcomes in early schizophrenia

Gagan Fervaha ^{a,b,*}, George Foussias ^{a,b,c}, Ofer Agid ^{a,c}, Gary Remington ^{a,b,c}




^a Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, ON, Canada


^b Institute of Medical Science, University of Toronto, Toronto, ON, Canada

^c Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

Predictors of Functional Outcomes in Schizophrenia




Predictors of Functional Outcomes in Schizophrenia





* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$
QLS = Quality of Life Scale

Pathways to Community Functioning in Schizophrenia



Cognitive Functioning and Motivational Deficits



Cognitive Functioning and Motivational Deficits



- Impact of motivation on cognition?
- Is poor performance on cognitive tasks due to lack of motivation to do well?

Cognitive Functioning and Motivational Deficits




- Improved performance with monetary incentives
 - Executive function
 - Attention
 - Social cognition
- Effort testing
 - Insufficient effort in 10-25% of patients
 - Amotivation in the cognitive realm
 - Accounts for up to 1/3 of the variance in cognitive test performance


Cognitive Functioning and Motivational Deficits

	Amotivation Composite Score (r)	Effort (TOMM) (r)
Effort (TOMM)	-.39**	
BACS Composite	-.43***	.39**
Verbal Memory	-.30*	ns
Working Memory	-.28*	.26*
Motor Speed	ns	ns
Verbal Fluency	-.49***	.41***
Attention/Processing Speed	-.25*	.30*
Executive Function	-.25*	.34**

ns. not significant; * p<.05; ** p<.01; *** p<.001; ^a p=.050; ^b p=.051.



Cognitive Functioning and Motivational Deficits




Objectives

- To review the phenomenology and functional consequences of motivational deficits in schizophrenia
- To examine behavioural impairments across discrete facets of motivation in schizophrenia
- To explore recent findings on the neurobiology of cost/effort valuation in schizophrenia

Motivation System Framework

- Multiple components to motivation:
 - hedonics or “liking”
 - reward prediction and “wanting”
 - cost-benefit analysis
 - generation and execution of goal-directed plans



Hedonic Experience in Schizophrenia






- **Anhedonia**
 - diminished capacity to experience interest or pleasure¹




Hedonic Experience in Schizophrenia

FIGURE 4. Proposed Components of Anhedonia^a



Hedonic Experience in Schizophrenia



Reward Prediction and "Wanting" in Schizophrenia

Train

まみ
A (80/20) B (20/80)

その
C (70/30) D (30/70)

らや
E (60/40) F (40/60)

Test

AC
AD
AE
AF

BC
BD
BE
BF

Choose A? Avoid B?

250ms
Cue

2.25-2.75s
Delay

1650ms
Target



+3
[+12.30]
Feedback

----- 1.- 3. scan ----- ||--- 4. - 6. scan ---

all cues:

[-3.00€] [-0.60€] [-0.10€] [0.00€] [+0.10€] [+0.60€] [+3.00€]

Reward Valuation in Schizophrenia





Effort Valuation in Schizophrenia

ARCHIVAL REPORT

Negative Symptoms of Schizophrenia Are Associated with Abnormal Effort-Cost Computations

James M. Gold, Gregory P. Strauss, James A. Waltz, Benjamin M. Robinson, Jamie K. Brown, and Michael J. Frank



Effort Valuation in Schizophrenia

Contents lists available at ScienceDirect




Journal of Psychiatric Research

journal homepage: www.elsevier.com/locate/psychires



Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making

Gagan Fervaha^{a,b,*}, Ariel Graff-Guerrero^{a,b,c}, Konstantine K. Zakzanis^d, George Foussias^{a,b,c}, Ofer Agid^{a,c}, Gary Remington^{a,b,c}



^aSchizophrenia Division, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, Canada M5T 1R8
^bInstitute of Medical Science, University of Toronto, Toronto, ON, Canada
^cDepartment of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
^dDepartment of Psychology, University of Toronto Scarborough Campus, Toronto, ON, Canada



Goal-Directed Planning and Action in Schizophrenia



Virtual Reality and Ecological Validity



Goal-Directed Planning and Action




```
Time: 02:32:08
Money: $ 16.67





Tasks Left:
Buy 6 blue pens
Collect package at the post office
send letters (buy postage) at the post office
Doctor's appointment before or at 12:10PM
Buy Groceries
Return home by 12:15PM

Completed Tasks:
Buy Cough syrup
Go to the Bank & withdraw money

Items in Bag:
1Money from bank
1Cough Syrup
```



Goal-Directed Planning and Action



Goal-Directed Planning and Action

Group Comparison




	SZ group (n=40) Mean (SD)	HC group (n=40) Mean (SD)	<i>t</i>	<i>p</i>	Effect Size (<i>d</i>)
Tasks Completed	7.5(1.4)	7.9(0.6)	1.45	ns	
Errors Committed	2.0(2.1)	1.2(1.3)	2.13	.036	0.48
Completion Time	518.0(290.7)	343.2(102.3)	3.70	.001	0.83
Distance Travelled	375.1(153.6)	315.4(79.2)	2.19	.033	0.49

Bivariate Correlations (overall sample, n = 80)


	Correlation (<i>r</i>)			
	Tasks Completed	Errors Committed	Completion Time	Distance Travelled
Intrinsic Motivation (QLS)	ns	-0.223*	-0.348**	-0.268*
Cognition (BACS Composite Z)	ns	-0.244*	-0.294**	-0.256*
Planning (BACS ToL)	ns	-0.233*	ns	ns
Motor Speed (BACS TMT)	ns	ns	ns	ns
Community Functioning (QLS)	ns	ns	-0.332**	-0.215(<i>p</i> =0.055)

* *p* < .05; ** *p* < .01; ns – not significant

Animals At Work



Effort Valuation in a Virtual Environment (ViPR)



Effort Valuation in a Virtual Environment (ViPR)




Navigation to store



Task completion phase:
Progressively increasing effort
requirement



Navigation to next store



Task completion phase:
points awarded




Effort Valuation in a Virtual Environment (ViPR)

Demographics	SZ (n=50)	HC (n=57)	p
	Mean (SD)	Mean (SD)	
Age	36.9 (10.6)	35.8 (11.6)	ns
Sex (M:F)	31:19	35:22	ns
Diagnosis			
Schizophrenia	38		
Schizoaffective Disorder	12		
Duration of Illness (yrs)	13.6 (10.0)		

	Bivariate Correlations (rho)		
	Points Earned	Task Completions	Task Completion Rate
Amotivation (n=107)	-.26**	-.25**	.29**
SZ Only (n=50)			
Amotivation	-.29*	-.41**	.37**
Positive symptoms	-	-	-
Diminished Expression	-	-	-
Depression	-	-	-
Anticipatory Pleasure	-	-	-
Consummatory Pleasure	-	-	-
Neurocognition	-	-	-
Motor speed	-	-	-

* p<.05; ** p<.01.


Effort Valuation in a Virtual Environment (ViPR)



Objectives



- To review the phenomenology and functional consequences of motivational deficits in schizophrenia
- To examine behavioural impairments across discrete facets of motivation in schizophrenia
- To explore recent findings on the neurobiology of cost/effort valuation in schizophrenia

Motivation System Framework





The Neurobiology of Effort Valuation in a Virtual Environment




The Neurobiology of Effort Valuation in a Virtual Environment



The Neurobiology of Effort Valuation in a Virtual Environment



The Neurobiology of Effort Valuation in a Virtual Environment



Novel Strategies for Treating Motivational Deficits?



Treatments for Negative Symptoms in Schizophrenia

Antidepressants

rTMS


Antipsychotics

Stimulants



Glutamatergic Agents




Novel Strategies for Treating Motivational Deficits?



Virtual Reality Therapy












Conclusions

- Motivational deficits
 - The critical link between negative symptoms and functional outcomes
 - Indirect role through cognitive function
 - Impact on cognitive test performance



Conclusions

- Hedonic capacity is intact in schizophrenia
- Deficits:
 - Reward prediction / “wanting”
 - Reward and Effort valuation
 - Cost-benefit analysis
 - Goal-directed planning and action
- Patient-specific deficits?



Conclusions

- Novel treatment strategies for motivational deficits in schizophrenia
 - Pharmacotherapy & Opportunity
 - Improved neurobiological understanding of specific deficits
 - VR rehabilitation?
 - Personalized treatment for specific deficits



Acknowledgements

Gary Remington

Konstantine Zakzanis

Paul Fletcher

Albert Wong

Ishraq Siddiqui

Gagan Fervaha

Colin Hawco

John Zawadzki

Nasteho Hasan

Krysta McDonald

Sathesan Thavabalasingam

Christina Plagiannakos

Areti Apatsidou

Sarah Saperia

